Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Kerr et al., Cureus, doi:10.7759/cureus.28624 (date from preprint)
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 92% Improvement Relative Risk Ivermectin for COVID-19  Kerr et al.  Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? PSM retrospective 566 patients in Brazil (July - December 2020) Lower mortality with ivermectin (p=0.0008) c19ivm.org Kerr et al., Cureus, February 2022 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
PSM multivariable analysis of the Itajaí trial showing significantly lower mortality with regular use of ivermectin prophylaxis. Immortal time bias may significantly affect these results. See Mills regarding2.
risk of death, 92.0% lower, RR 0.08, p < 0.001, treatment 2 of 283 (0.7%), control 15 of 283 (5.3%), NNT 22, adjusted per study, strictly regular use vs. non-use, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kerr et al., 6 Feb 2022, retrospective, propensity score matching, multivariable, Brazil, peer-reviewed, 9 authors, study period 7 July, 2020 - 2 December, 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.
This PaperIvermectinAll
Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra, Fernando Carlos Proença, Juan J Chamie, Jennifer A Hibberd, Pierre Kory, Flavio A Cadegiani
Cureus, doi:10.7759/cureus.28624
Background We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 , irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a doseresponse effect. Methods This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates. Results Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR:..
Discussion The program in Itajaí, Brazil: ivermectin prophylaxis for COVID-19 The present study provides in-depth results on the prospective study of ivermectin as prophylaxis for COVID-19 in Itajaí, located in Southern Brazil. Particularities of Itajaí included its dynamic population due to the presence of an overwhelmingly large port compared to the size of the city. This explained why the city was one of the first in the state to reach 1,000 cases in 2020 [26] . In the past, the city experienced some of the highest rates of HIV infections in Brazil [27] , partially substantiated by being a port city, an "independent" predictor of a higher prevalence of HIV infection [28] . The decision to adopt a prophylaxis program with ivermectin in Itajaí was based on (1) the fact that case numbers rose rapidly and at a higher speed than in other cities; (2) the inability to isolate port workers in the absence of pharmacological or non-pharmacological therapies for COVID-19; (3) because it had already been proven to be a potent antiviral for over 20 viruses, studied independently and peer-reviewed, including the first severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic before the COVID-19 pandemic; and (4) the extensive safety profile and favorable cost-effectiveness of ivermectin. Hence, the program of Itajaí strictly followed all bioethical principles using ivermectin as prophylaxis for COVID-19. The ivermectin was offered optionally, as prophylaxis for..
References
Andersson, Ottestad, Tracey, Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?, Mol Med, doi:10.1186/s10020-020-00172-4
Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163
Boing, Lunardon, Trend in the mortality and incidence from AIDS in Itajaí (Santa Catarina) between 1990 and 2005. (Article in Portuguese), Arch Catarin Med
Cairns, Giordano, Conte, Levin, Kaplan, Ivermectin promotes peripheral nerve regeneration during wound healing, ACS Omega, doi:10.1021/acsomega.8b01451
Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot, doi:10.1038/ja.2017.11
Dou, Chen, Wang, Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer, Cancer Res, doi:10.1158/0008-5472.CAN-15-2887
Eichler, Pignatti, Schwarzer-Daum, Randomized controlled trials versus real world evidence: neither magic nor myth, Clin Pharmacol Ther, doi:10.1002/cpt.2083
Franklin, Schneeweiss, When and how can real world data analyses substitute for randomized controlled trials?, Clin Pharmacol Ther, doi:10.1002/cpt.857
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Hellwig, A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106248
Jin, Feng, Rong, The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism, Nat Commun, doi:10.1038/ncomms2924
Juarez, Schcolnik-Cabrera, Dueñas-Gonzalez, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Am J Cancer Res
Kalfas, Visvanathan, Drago, The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence, PREPRINT, doi:10.1101/2020.11.30.20236570
Kaur, Shekhar, Sharma, Sarma, Prakash et al., Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes, Pharmacol Rep, doi:10.1007/s43440-020-00195-y
Kerr, Cadegiani, Baldi, Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching, Cureus, doi:10.7759/cureus.21272
Layhadi, Turner, Crossman, Fountain, ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages, J Immunol, doi:10.4049/jimmunol.1700965
Li, Zhao, Zhan, Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment, J Cell Physiol, doi:10.1002/jcp.30055
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother, doi:10.1093/jac/dks147
Matsuyama, Kubli, Yoshinaga, Pfeffer, Mak, An aberrant STAT pathway is central to COVID-19, Cell Death Differ, doi:10.1038/s41418-020-00633-7
Nagai, Satomi, Abiru, Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia, EBioMedicine, doi:10.1016/j.ebiom.2017.09.022
Park, Iwasaki, Type I and type III interferons -induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe, doi:10.1016/j.chom.2020.05.008
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150
Wang, Schneeweiss, Gagne, Evers, Gerlinger et al., Using real-world data to extrapolate evidence from randomized controlled trials, Clin Pharmacol Ther, doi:10.1002/cpt.1210
Yan, Ci, Chen, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8
Yang, Qi, Farias-Pereira, Choi, Clark et al., Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte, Food Chem Toxicol, doi:10.1016/j.fct.2019.02.005
Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review, J Antibiot, doi:10.1038/s41429-021-00491-6
Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2: an evidencebased clinical review article, J Antibiot, doi:10.1038/s41429-021-00430-5
Zhang, Hospital avoidance and unintended deaths during the COVID-19 pandemic, Am J Health Econ, doi:10.1086/715158
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8
Zheng, Ma, Zhang, Xie, COVID-19 and the cardiovascular system, Nat Rev Cardiol, doi:10.1038/s41569-020-0360-5
{ 'indexed': {'date-parts': [[2022, 8, 31]], 'date-time': '2022-08-31T13:12:03Z', 'timestamp': 1661951523588}, 'reference-count': 32, 'publisher': 'Cureus, Inc.', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 8, 31]]}, 'DOI': '10.7759/cureus.28624', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 31]], 'date-time': '2022-08-31T12:40:16Z', 'timestamp': 1661949616000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 ' 'Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a ' 'Strictly Controlled Population of 88,012 Subjects', 'prefix': '10.7759', 'author': [ {'given': 'Lucy', 'family': 'Kerr', 'sequence': 'first', 'affiliation': []}, {'given': 'Fernando', 'family': 'Baldi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Raysildo', 'family': 'Lobo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Washington Luiz', 'family': 'Assagra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fernando Carlos', 'family': 'Proença', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan J', 'family': 'Chamie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jennifer A', 'family': 'Hibberd', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pierre', 'family': 'Kory', 'sequence': 'additional', 'affiliation': []}, {'given': 'Flavio A', 'family': 'Cadegiani', 'sequence': 'additional', 'affiliation': []}], 'member': '4492', 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo E', 'year': '2012', 'unstructured': 'Mastrangelo E, Pezzullo M, De Burghgraeve T, et al.. Ivermectin is a ' 'potent inhibitor of flavivirus replication specifically targeting NS3 ' 'helicase activity: new prospects for an old drug. J Antimicrob ' 'Chemother. 2012, 67:1884-94. 10.1093/jac/dks147', 'journal-title': 'J Antimicrob Chemother'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Wagstaff KM', 'year': '2012', 'unstructured': 'Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is ' 'a specific inhibitor of importin α/β-mediated nuclear import able to ' 'inhibit replication of HIV-1 and dengue virus. Biochem J. 2012, ' '443:851-6. 10.1042/BJ20120150', 'journal-title': 'Biochem J'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/ja.2017.11', 'article-title': "Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise " 'and exceed expectations', 'volume': '70', 'author': 'Crump A', 'year': '2017', 'unstructured': "Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to " 'surprise and exceed expectations. J Antibiot (Tokyo). 2017, 70:495-505. ' '10.1038/ja.2017.11', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'volume': '73', 'author': 'Heidary F', 'year': '2020', 'unstructured': 'Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral ' 'effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020, ' '73:593-602. 10.1038/s41429-020-0336-z', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jcp.30055', 'article-title': 'Quantitative proteomics reveals a broad-spectrum antiviral property of ' 'ivermectin, benefiting for COVID-19 treatment', 'volume': '236', 'author': 'Li N', 'year': '2021', 'unstructured': 'Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum ' 'antiviral property of ivermectin, benefiting for COVID-19 treatment. J ' 'Cell Physiol. 2021, 236:2959-75. 10.1002/jcp.30055', 'journal-title': 'J Cell Physiol'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/ncomms2924', 'article-title': 'The antiparasitic drug ivermectin is a novel FXR ligand that regulates ' 'metabolism', 'volume': '4', 'author': 'Jin L', 'year': '2013', 'unstructured': 'Jin L, Feng X, Rong H, et al.. The antiparasitic drug ivermectin is a ' 'novel FXR ligand that regulates metabolism. Nat Commun. 2013, 4:1937. ' '10.1038/ncomms2924', 'journal-title': 'Nat Commun'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.fct.2019.02.005', 'article-title': 'Permethrin and ivermectin modulate lipid metabolism in ' 'steatosis-induced HepG2 hepatocyte', 'volume': '125', 'author': 'Yang JS', 'year': '2019', 'unstructured': 'Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. ' 'Permethrin and ivermectin modulate lipid metabolism in steatosis-induced ' 'HepG2 hepatocyte. Food Chem Toxicol. 2019, 125:595-604. ' '10.1016/j.fct.2019.02.005', 'journal-title': 'Food Chem Toxicol'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acsomega.8b01451', 'article-title': 'Ivermectin promotes peripheral nerve regeneration during wound healing', 'volume': '3', 'author': 'Cairns DM', 'year': '2018', 'unstructured': 'Cairns DM, Giordano JE, Conte S, Levin M, Kaplan DL. Ivermectin promotes ' 'peripheral nerve regeneration during wound healing. ACS Omega. 2018, ' '3:12392-402. 10.1021/acsomega.8b01451', 'journal-title': 'ACS Omega'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41569-020-0360-5', 'article-title': 'COVID-19 and the cardiovascular system', 'volume': '17', 'author': 'Zheng YY', 'year': '2020', 'unstructured': 'Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular ' 'system. Nat Rev Cardiol. 2020, 17:259-60. 10.1038/s41569-020-0360-5', 'journal-title': 'Nat Rev Cardiol'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ebiom.2017.09.022', 'article-title': 'Antihypertrophic effects of small molecules that maintain mitochondrial ' 'ATP levels under hypoxia', 'volume': '24', 'author': 'Nagai H', 'year': '2017', 'unstructured': 'Nagai H, Satomi T, Abiru A, et al.. Antihypertrophic effects of small ' 'molecules that maintain mitochondrial ATP levels under hypoxia. ' 'EBioMedicine. 2017, 24:147-58. 10.1016/j.ebiom.2017.09.022', 'journal-title': 'EBioMedicine'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chom.2020.05.008', 'article-title': 'Type I and type III interferons - induction, signaling, evasion, and ' 'application to combat COVID-19', 'volume': '27', 'author': 'Park A', 'year': '2020', 'unstructured': 'Park A, Iwasaki A. Type I and type III interferons - induction, ' 'signaling, evasion, and application to combat COVID-19. Cell Host ' 'Microbe. 2020, 27:870-8. 10.1016/j.chom.2020.05.008', 'journal-title': 'Cell Host Microbe'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00011-008-8007-8', 'article-title': 'Ivermectin inhibits LPS-induced production of inflammatory cytokines ' 'and improves LPS-induced survival in mice', 'volume': '57', 'author': 'Zhang X', 'year': '2008', 'unstructured': 'Zhang X, Song Y, Ci X, et al.. Ivermectin inhibits LPS-induced ' 'production of inflammatory cytokines and improves LPS-induced survival ' 'in mice. Inflamm Res. 2008, 57:524-9. 10.1007/s00011-008-8007-8', 'journal-title': 'Inflamm Res'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41429-021-00491-6', 'article-title': 'The mechanisms of action of ivermectin against SARS-CoV-2-an extensive ' 'review', 'volume': '75', 'author': 'Zaidi AK', 'year': '2022', 'unstructured': 'Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin ' 'against SARS-CoV-2-an extensive review. J Antibiot (Tokyo). 2022, ' '75:60-71. 10.1038/s41429-021-00491-6', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41418-020-00633-7', 'article-title': 'An aberrant STAT pathway is central to COVID-19', 'volume': '27', 'author': 'Matsuyama T', 'year': '2020', 'unstructured': 'Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT ' 'pathway is central to COVID-19. Cell Death Differ. 2020, 27:3209-25. ' '10.1038/s41418-020-00633-7', 'journal-title': 'Cell Death Differ'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1158/0008-5472.CAN-15-2887', 'article-title': 'Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis ' 'in breast cancer', 'volume': '76', 'author': 'Dou Q', 'year': '2016', 'unstructured': 'Dou Q, Chen HN, Wang K, et al.. Ivermectin induces cytostatic autophagy ' 'by blocking the PAK1/Akt axis in breast cancer. Cancer Res. 2016, ' '76:4457-69. 10.1158/0008-5472.CAN-15-2887', 'journal-title': 'Cancer Res'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.4049/jimmunol.1700965', 'article-title': 'ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor ' 'activation in human monocyte-derived macrophages', 'volume': '200', 'author': 'Layhadi JA', 'year': '2018', 'unstructured': 'Layhadi JA, Turner J, Crossman D, Fountain SJ. ATP evokes Ca2+ responses ' 'and CXCL5 secretion via P2X4 receptor activation in human ' 'monocyte-derived macrophages. J Immunol. 2018, 200:1159-68. ' '10.4049/jimmunol.1700965', 'journal-title': 'J Immunol'}, { 'key': 'ref17', 'article-title': 'The multitargeted drug ivermectin: from an antiparasitic agent to a ' 'repositioned cancer drug', 'volume': '8', 'author': 'Juarez M', 'year': '2018', 'unstructured': 'Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ' 'ivermectin: from an antiparasitic agent to a repositioned cancer drug. ' 'Am J Cancer Res. 2018, 8:317-31.', 'journal-title': 'Am J Cancer Res'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s10020-020-00172-4', 'article-title': 'Extracellular HMGB1: a therapeutic target in severe pulmonary ' 'inflammation including COVID-19?', 'volume': '26', 'author': 'Andersson U', 'year': '2020', 'unstructured': 'Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic ' 'target in severe pulmonary inflammation including COVID-19?. Mol Med. ' '2020, 26:42. 10.1186/s10020-020-00172-4', 'journal-title': 'Mol Med'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00011-011-0307-8', 'article-title': 'Anti-inflammatory effects of ivermectin in mouse model of allergic ' 'asthma', 'volume': '60', 'author': 'Yan S', 'year': '2011', 'unstructured': 'Yan S, Ci X, Chen N, et al.. Anti-inflammatory effects of ivermectin in ' 'mouse model of allergic asthma. Inflamm Res. 2011, 60:589-96. ' '10.1007/s00011-011-0307-8', 'journal-title': 'Inflamm Res'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s43440-020-00195-y', 'article-title': 'Ivermectin as a potential drug for treatment of COVID-19: an in-sync ' 'review with clinical and computational attributes', 'volume': '73', 'author': 'Kaur H', 'year': '2021', 'unstructured': 'Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as ' 'a potential drug for treatment of COVID-19: an in-sync review with ' 'clinical and computational attributes. Pharmacol Rep. 2021, 73:736-49. ' '10.1007/s43440-020-00195-y', 'journal-title': 'Pharmacol Rep'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41429-021-00430-5', 'article-title': 'The mechanisms of action of ivermectin against SARS-CoV-2: an ' 'evidence-based clinical review article', 'volume': '75', 'author': 'Zaidi AK', 'year': '2022', 'unstructured': 'Zaidi AK, Dehgani-Mobaraki P. The mechanisms of action of ivermectin ' 'against SARS-CoV-2: an evidence-based clinical review article. J ' 'Antibiot (Tokyo). 2022, 75:122. 10.1038/s41429-021-00430-5', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.11.30.20236570', 'article-title': 'The therapeutic potential of ivermectin for COVID-19: a systematic ' 'review of mechanisms and evidence. [PREPRINT]', 'author': 'Kalfas S', 'year': '2020', 'unstructured': 'Kalfas S, Visvanathan K, Chan K Drago J. The therapeutic potential of ' 'ivermectin for COVID-19: a systematic review of mechanisms and evidence. ' '[PREPRINT]. medRxiv. 2020, 10.1101/2020.11.30.20236570', 'journal-title': 'medRxiv'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0247163', 'article-title': 'Role of ivermectin in the prevention of SARS-CoV-2 infection among ' 'healthcare workers in India: a matched case-control study', 'volume': '16', 'author': 'Behera P', 'year': '2021', 'unstructured': 'Behera P, Patro BK, Singh AK, et al.. Role of ivermectin in the ' 'prevention of SARS-CoV-2 infection among healthcare workers in India: a ' 'matched case-control study. PLoS One. 2021, 16:e0247163. ' '10.1371/journal.pone.0247163', 'journal-title': 'PLoS One'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.106248', 'article-title': 'A COVID-19 prophylaxis? Lower incidence associated with prophylactic ' 'administration of ivermectin', 'volume': '57', 'author': 'Hellwig MD', 'year': '2021', 'unstructured': 'Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated ' 'with prophylactic administration of ivermectin. Int J Antimicrob Agents. ' '2021, 57:106248. 10.1016/j.ijantimicag.2020.106248', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.7759/cureus.21272', 'article-title': 'Ivermectin prophylaxis used for COVID-19: a citywide, prospective, ' 'observational study of 223,128 subjects using propensity score matching', 'volume': '14', 'author': 'Kerr L', 'year': '2022', 'unstructured': 'Kerr L, Cadegiani FA, Baldi F, et al.. Ivermectin prophylaxis used for ' 'COVID-19: a citywide, prospective, observational study of 223,128 ' 'subjects using propensity score matching. Cureus. 2022, 14:e21272. ' '10.7759/cureus.21272', 'journal-title': 'Cureus'}, { 'key': 'ref26', 'unstructured': 'Coronavirus epidemiological data - State of Santa Catarina. (2022). ' 'Accessed. July 8, 2022: ' 'https://itajai.sc.gov.br/noticias/59/boletins-coronavirus.'}, { 'key': 'ref27', 'article-title': 'Trend in the mortality and incidence from AIDS in Itajaí (Santa ' 'Catarina) between 1990 and 2005. (Article in Portuguese)', 'volume': '38', 'author': 'Boing AF', 'year': '2009', 'unstructured': 'Boing AF, Lunardon C. Trend in the mortality and incidence from AIDS in ' 'Itajaí (Santa Catarina) between 1990 and 2005. (Article in Portuguese). ' 'Arch Catarin Med. 2009, 38:59-65.', 'journal-title': 'Arch Catarin Med'}, { 'key': 'ref28', 'unstructured': 'HIV/AIDS and port workers. a resource pack for unions. (2013). Accessed: ' 'January 22, 2021: ' 'https://www.itfglobal.org/sites/default/files/resources-files/HIV_AIDS_portworkers.pdf.'}, { 'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1086/715158', 'article-title': 'Hospital avoidance and unintended deaths during the COVID-19 pandemic', 'volume': '7', 'author': 'Zhang J', 'year': '2021', 'unstructured': 'Zhang J. Hospital avoidance and unintended deaths during the COVID-19 ' 'pandemic. Am J Health Econ. 2021, 7:405-26. 10.1086/715158', 'journal-title': 'Am J Health Econ'}, { 'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.2083', 'article-title': 'Randomized controlled trials versus real world evidence: neither magic ' 'nor myth', 'volume': '109', 'author': 'Eichler HG', 'year': '2021', 'unstructured': 'Eichler HG, Pignatti F, Schwarzer-Daum B, et al.. Randomized controlled ' 'trials versus real world evidence: neither magic nor myth. Clin ' 'Pharmacol Ther. 2021, 109:1212-8. 10.1002/cpt.2083', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1210', 'article-title': 'Using real-world data to extrapolate evidence from randomized ' 'controlled trials', 'volume': '105', 'author': 'Wang SV', 'year': '2019', 'unstructured': 'Wang SV, Schneeweiss S, Gagne JJ, Evers T, Gerlinger C, Desai R, ' 'Najafzadeh M. Using real-world data to extrapolate evidence from ' 'randomized controlled trials. Clin Pharmacol Ther. 2019, 105:1156-63. ' '10.1002/cpt.1210', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.857', 'article-title': 'When and how can real world data analyses substitute for randomized ' 'controlled trials?', 'volume': '102', 'author': 'Franklin JM', 'year': '2017', 'unstructured': 'Franklin JM, Schneeweiss S. When and how can real world data analyses ' 'substitute for randomized controlled trials?. Clin Pharmacol Ther. 2017, ' '102:924-33. 10.1002/cpt.857', 'journal-title': 'Clin Pharmacol Ther'}], 'container-title': 'Cureus', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 8, 31]], 'date-time': '2022-08-31T12:40:21Z', 'timestamp': 1661949621000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 8, 31]]}, 'references-count': 32, 'URL': 'http://dx.doi.org/10.7759/cureus.28624', 'relation': {}, 'ISSN': ['2168-8184'], 'subject': ['Aerospace Engineering'], 'published': {'date-parts': [[2022, 8, 31]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit